| pathology | treatment | patient | Demonstrated benefit and harm | k | | | |
|---|
| post myocardial infarction | aspirin | not classified | versus placebo or control No demonstrated result for efficacy | 8 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| CDPA, 1976 | aspirin vs placebo | | | Total mortality 0.70 [0.48; 1.01] Cardiovascular death 0.70 [0.47; 1.02] Non-fatal MI 0.89 [0.54; 1.46] | | Cardiff I, 1974 | aspirin vs placebo | | | Total mortality 0.74 [0.52; 1.05] | | Cardiff II, 1979 | aspirin vs placebo | | | Total mortality 0.83 [0.65; 1.05] | | Vogel, 1979 | aspirin vs placebo | Cardiovascular death 0.50 [0.27; 0.92] Fatal MI 0.38 [0.17; 0.85] Non-fatal MI 0.47 [0.29; 0.75] | | Total mortality 0.68 [0.44; 1.05] | | AMIS, 1980 | aspirin vs placebo | Non-fatal MI 0.78 [0.63; 0.96] | | Total mortality 1.11 [0.94; 1.32] | | GAMIS, 1980 | aspirin vs placebo | | | Total mortality 0.82 [0.51; 1.34] Fatal MI 0.49 [0.17; 1.41] Non-fatal MI 0.71 [0.33; 1.53] | | PARIS, 1980 | aspirin vs placebo | | | Total mortality 0.82 [0.59; 1.13] Cardiovascular death 0.82 [0.58; 1.17] Non-fatal MI 0.70 [0.48; 1.03] | | JAMIS, 1999 | aspirin vs placebo | Non-fatal MI 0.27 [0.10; 0.72] | | Total mortality 1.18 [0.45; 3.12] Cardiovascular death 1.10 [0.34; 3.57] |
| Trial | Treatments | Patients | Method |
|---|
| CDPA, 1976 | Aspirin (324 mg) 3x/d (n=758) vs. Placebo (n=771) | MI survivors | Double blind Parallel groups Sample size: 758/771 Primary endpoint: No primary outcome clearly defined FU duration: 1.83 y | | Cardiff I, 1974 | Aspirin (300 mg) 1x/d (n=615) vs. Placebo (n=624) | MI survivors | Double blind Parallel groups Sample size: 615/624 Primary endpoint: Total mortality FU duration: 2 years | | Cardiff II, 1979 | Aspirin (300 mg) 3x/d for one year (n=832) vs. Placebo (n=850) | patients with myocardial infarction | Double blind Parallel groups Sample size: 832/850 Primary endpoint: Total mortality FU duration: 1 y | | Vogel, 1979 | Aspirin (1.5 g daily) on an average period of 22 months
(n=672) vs. Placebo
(n=668) | | Double blind Parallel groups Sample size: 672/668 Primary endpoint: Death or reinfraction FU duration: 1.75 y (mean) | | AMIS, 1980 | Aspirin (500 mg) 2x/d for at least 3 years (n=2267) vs. Placebo (n=2257) | men and women who had had a documented myocardial infarction | Double blind Parallel groups Sample size: 2267/2257 Primary endpoint: Total mortality FU duration: > 3 y | | GAMIS, 1980 | Aspirin (500 mg) 3x/d for 2 years (n=317) vs. Placebo (n=309) | patients who had survived a myocardial infarction for 30-42 days | Double blind Parallel groups Sample size: 317/309 Primary endpoint: No primary outcome clearly defined FU duration: 2 y part of a 3-group trial | | PARIS, 1980 | Aspirin (324 mg) 3x/d (n=810) vs. Placebo (n=406) | patients who had recovered from myocardial infarction | Double blind Parallel groups Sample size: 810/406 Primary endpoint: No primary outcome clearly defined FU duration: 41 mo part of 3-group trial | | JAMIS, 1999 | Aspirin (81 mg) 1x/d (n=250) vs. No antiplatelets (n=230) | patients with AMI within 1 month from the onset of symptoms | Open Parallel groups Sample size: 250/230 Primary endpoint: No primary outcome clearly defined FU duration: 1.3 y (mean) part of a 3-group trial |
|
| post myocardial infarction | clopidogrel | not classified | versus aspirin No demonstrated result for efficacy | 1 trial | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| CAPRIE, 1996 | clopidogrel vs aspirin | | | |
| Trial | Treatments | Patients | Method |
|---|
| CAPRIE, 1996 | Clopidogrel (75 mg) 1x/d for a minimum of one year and a maximum of 3 years (n=9599) vs. Aspirin (325 mg) 1x/d (n=9586) | patients with atherosclerotic vascular disease manifested as either recent ischaemic stroke, recent myocardial infarction, or symptomatic peripheral arterial disease | Double blind Parallel groups Sample size: 9599/9586 Primary endpoint: ischaemic stroke, myocardial infarction, vascular death FU duration: 1.91 y |
|
| post myocardial infarction | dipyridamol | not classified | versus placebo or control No demonstrated result for efficacy | 2 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| PARIS, 1980 | dipyridamol + aspirin vs placebo | | | Stroke 0.63 [0.25; 1.58] | | PARIS-II, 1986 | dipyridamol + aspirin vs placebo | | | Stroke 0.61 [0.35; 1.05] |
| Trial | Treatments | Patients | Method |
|---|
| PARIS, 1980 | Aspirin (324 mg) + dipyridamole (75 mg) 3x/d (n=810) vs. Placebo (n=406) | patients who had recovered from myocardial infarction | Double blind Parallel groups Sample size: 810/406 Primary endpoint: No primary outcome clearly defined FU duration: 41 months (mean) part of 3-group trial | | PARIS-II, 1986 | Aspirin (330 mg) + dipyridamole (75 mg) 3x/d (n=1563) vs. Placebo (n=1565) | patients who had recovered from myocardial infarction, suffered from 4 weeks to 4 months previously | Double blind Parallel groups Sample size: 1563/1565 Primary endpoint: No primary outcome clearly defined FU duration: 23.4 months |
|
| post myocardial infarction | dipyridamol | not classified | versus aspirin No demonstrated result for efficacy | 1 trial | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| PARIS, 1980 | dipyridamol + aspirin vs aspirin | | | Death or nonfatal MI 1.05 [0.84; 1.30] |
| Trial | Treatments | Patients | Method |
|---|
| PARIS, 1980 | Aspirin (324 mg) + dipyridamole (75 mg) 3x/d (n=810) vs. Aspirin (324 mg) 3x/d (n=810) | patuents who had recovered from myocardial infarction | Double blind Parallel groups Sample size: 810/810 Primary endpoint: No primary outcome clearly defined FU duration: 41 months part of 3-group trial |
|
